المصدر: MarketBeat
وكالة أنباء
الأسهم
أهمية متوسطة
Ocugen Q2 Earnings Call Highlights
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
الرموز ذات الصلة
1
O
OCGN
OCGN
المصدر: MarketBeat
زيارة المصدر